Cleansing Notice and Appendix 2A

RNS Number : 7498E

MGC Pharmaceuticals Limited

09 July 2021

 

Issue of Shares - Cleansing Notice

09 July 2021

ASX, LSE: MXC

MGC Pharmaceuticals Ltd (ASX: MXC, 'MGC Pharma' or 'the Company') wishes to advise that it has recently issued the following fully paid ordinary shares ( Shares ) in the Company:

1.  Issued 55,555 Shares following the exercise of $0.045 Listed Options for a total consideration of $2,499.98.

Cleansing Notice:

Pursuant to section 708A(5)(e) of the Corporations Act 2001 (Cth) (Corporations Act), the Company gives notice in relation to the 55,555 Shares issued on the exercise of the Options and Performance Rights noted above, that:

(a)  the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act; and

(b)  as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Corporations Act as they apply to the Company;

(c)  as at the date of this notice, the Company has complied with section 674 of the Corporations Act as it applies to the Company; and

(d)  as at the date of this notice, there is no information to be disclosed which is "excluded information" as defined in subsection 708A(7) of the Corporations Act that is reasonable for investors and their professional advisors to find in a disclosure document.

Further information can be found here

-Ends-

Authorised for release by David Lim, Company Secretary, further information, please contact:

MGC Pharmaceuticals Ltd Roby Zomer CEO & Managing Director [phone] [e-mail]	PR/IR Advisors - Media & Capital Partners Rod Hinchcliffe (IR) [phone] [e-mail]
UK Broker - Turner Pope Andy Thacker [e-mail] Zoe Alexander [phone] [e-mail]	UK PR Advisors - Tavistock Charles Vivian [phone] [e-mail] Tim Pearson [phone] [e-mail]

About MGC Pharma

MGC Pharmaceuticals Ltd (LSE: MXC, ASX: MXC) is a European based bio-pharma company developing and supplying affordable standardised phytocannabinoid derived medicines to patients globally.  The Company's founders were key figures in the global medical cannabis industry and the core business strategy is to develop and supply high quality phytocannabinoid derived medicines for the growing demand in the medical markets in Europe, North America and Australasia. MGC Pharma has a robust product offering targeting two widespread medical conditions - epilepsy and dementia - and has further products in the development pipeline.

Employing its 'Nature to Medicine' strategy, MGC Pharma has partnered with renowned institutions and academia to optimise cultivation and the development of targeted phytocannabinoid derived medicines products prior to production in the Company's EU-GMP Certified manufacturing facility.  

MGC Pharma has a number of research collaborations with world renowned academic institutions, and including recent research highlighting the positive impact of using specific phytocannabinoid formulations developed by MGC Pharma in the treatment of glioblastoma, the most aggressive and so far therapeutically resistant primary brain tumour.

MGC Pharma has a growing patient base in Australia, the UK, Brazil and Ireland and has a global distribution footprint via an extensive network of commercial partners meaning that it is poised to supply the global market. 

Follow us through our social media channels :

  Twitter: @MGC_Pharma

Facebook: @mgcpharmaceuticals

LinkedIn: MGC Pharmaceuticals Ltd.

Instagram: @mgc_pharma

 

END

 

 

MSCDKCBDFBKKBOK